SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Omega Therapeutics, Inc. – ‘10-K’ for 12/31/23 – ‘EXCEL’

On:  Thursday, 3/28/24, at 4:31pm ET   ·   For:  12/31/23   ·   Accession #:  950170-24-38094   ·   File #:  1-40657

Previous ‘10-K’:  ‘10-K/A’ on 3/24/23 for 12/31/22   ·   Latest ‘10-K’:  This Filing   ·   13 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/28/24  Omega Therapeutics, Inc.          10-K       12/31/23   94:15M                                    Donnelley … Solutions/FA

Annual Report   —   Form 10-K   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.51M 
 3: EX-10.12    Material Contract                                   HTML     31K 
 4: EX-10.13    Material Contract                                   HTML     31K 
 5: EX-10.18    Material Contract                                   HTML     54K 
 6: EX-10.20    Material Contract                                   HTML     54K 
 7: EX-10.22    Material Contract                                   HTML     53K 
 8: EX-10.33    Material Contract                                   HTML    596K 
 2: EX-10.9     Material Contract                                   HTML    123K 
 9: EX-23.1     Consent of Expert or Counsel                        HTML     27K 
14: EX-97       Clawback Policy re: Recovery of Erroneously         HTML     43K 
                Awarded Compensation                                             
10: EX-31.1     Certification -- §302 - SOA'02                      HTML     33K 
11: EX-31.2     Certification -- §302 - SOA'02                      HTML     33K 
12: EX-32.1     Certification -- §906 - SOA'02                      HTML     30K 
13: EX-32.2     Certification -- §906 - SOA'02                      HTML     29K 
16: R1          Document and Entity Information                     HTML    101K 
17: R2          Consolidated Balance Sheets                         HTML    130K 
18: R3          Consolidated Balance Sheets (Parenthetical)         HTML     46K 
19: R4          Consolidated Statements of Operations and           HTML     95K 
                Comprehensive Loss                                               
20: R5          Consolidated Statements of Stockholders' Equity     HTML     69K 
21: R6          Consolidated Statements of Cash Flows               HTML    128K 
22: R7          Pay vs Performance Disclosure                       HTML     39K 
23: R8          Insider Trading Arrangements                        HTML     33K 
24: R9          Nature of the Business and Basis of Presentation    HTML     42K 
25: R10         Summary of Significant Accounting Policies          HTML     89K 
26: R11         Marketable Securities                               HTML     50K 
27: R12         Prepaid Expenses and Other Current Assets           HTML     52K 
28: R13         Property and Equipment, Net                         HTML     54K 
29: R14         Accrued Expenses                                    HTML     50K 
30: R15         Term Loan                                           HTML     75K 
31: R16         Fair Value of Financial Instruments                 HTML     99K 
32: R17         Commitments and Contingencies                       HTML     99K 
33: R18         License Agreements                                  HTML     53K 
34: R19         Collaboration Agreement                             HTML     46K 
35: R20         Preferred and Common Stock                          HTML     39K 
36: R21         Equity Incentive Plans                              HTML    115K 
37: R22         Net Loss Per Share Attributable to Common           HTML     53K 
                Stockholders                                                     
38: R23         Income Taxes                                        HTML     99K 
39: R24         Related Party Transactions                          HTML     47K 
40: R25         Employee Benefits                                   HTML     32K 
41: R26         Summary of Significant Accounting Policies          HTML    148K 
                (Policies)                                                       
42: R27         Summary of Significant Accounting Policies          HTML     33K 
                (Tables)                                                         
43: R28         Marketable Securities (Tables)                      HTML     45K 
44: R29         Prepaid Expenses and Other Current Assets (Tables)  HTML     52K 
45: R30         Property and Equipment, Net (Tables)                HTML     52K 
46: R31         Accrued Expenses (Tables)                           HTML     49K 
47: R32         Term Loan (Tables)                                  HTML     64K 
48: R33         Fair Value of Financial Instruments (Tables)        HTML    150K 
49: R34         Commitments and Contingencies (Tables)              HTML     77K 
50: R35         Equity Incentive Plans (Tables)                     HTML    102K 
51: R36         Net Loss Per Share Attributable to Common           HTML     54K 
                Stockholders (Tables)                                            
52: R37         Income Taxes (Tables)                               HTML     91K 
53: R38         Nature of the Business and Basis of Presentation -  HTML     53K 
                Additional Information (Details)                                 
54: R39         Summary of Significant Accounting Policies -        HTML     65K 
                Additional Information (Details)                                 
55: R40         Summary of Significant Accounting Policies -        HTML     37K 
                Summary of Estimated Useful Life of Each Asset                   
                Category (Details)                                               
56: R41         Marketable Securities - Summary of Marketable       HTML     39K 
                Securities (Details)                                             
57: R42         Marketable Securities - Additional Information      HTML     35K 
                (Details)                                                        
58: R43         Prepaid Expenses and Other Current Assets -         HTML     42K 
                Summary of Prepaid Expenses and other Current                    
                Assets (Details)                                                 
59: R44         Property and Equipment, Net - Summary of Property   HTML     46K 
                and Equipment, Net (Details)                                     
60: R45         Property and Equipment, Net - Additional            HTML     29K 
                Information (Details)                                            
61: R46         Accrued Expenses - Summary of Accrued Expenses      HTML     41K 
                (Details)                                                        
62: R47         Term Loan - Additional Information (Details)        HTML     82K 
63: R48         Term Loan - Summary of Outstanding Term Loan        HTML     36K 
                Balance (Details)                                                
64: R49         Term Loan - Summary of Interest Expense Recognized  HTML     35K 
                Related to Term loan (Details)                                   
65: R50         Term Loan - Schedule of Principal Amount in         HTML     41K 
                Connection With Term Loan (Details)                              
66: R51         Fair Value of Financial Instruments - Summary of    HTML     47K 
                Fair Value of Financial Instruments (Details)                    
67: R52         Fair Value of Financial Instruments - Additional    HTML     35K 
                Information (Details)                                            
68: R53         Fair Value of Financial Instruments - Summary of    HTML     42K 
                Significant Quantitative Inputs Used to Determine                
                Valuation of Success Fee Obligation (Details)                    
69: R54         Fair Value of Financial Instruments - Summary of    HTML     40K 
                Fair Values of Success Fee Obligation (Details)                  
70: R55         Commitments and Contingencies - Additional          HTML    165K 
                Information (Details)                                            
71: R56         Commitments and Contingencies - Summary of          HTML     34K 
                Components of Lease Expense (Details)                            
72: R57         Commitments and Contingencies - Summary of          HTML     32K 
                Weighted Average Remaining Lease Term And Discount               
                Rate Related to Leases (Details)                                 
73: R58         Commitments and Contingencies - Summary of          HTML     32K 
                Supplemental Cash Flow Information Relating to                   
                Leases (Details)                                                 
74: R59         Commitments and Contingencies - Summary of          HTML     46K 
                Estimated Minimum Lease Payments (Details)                       
75: R60         License Agreements - Additional Information         HTML     86K 
                (Details)                                                        
76: R61         Collaboration Agreement - Additional Information    HTML     49K 
                (Details)                                                        
77: R62         Redeemable Convertible Preferred Stock -            HTML     34K 
                Additional Information (Details)                                 
78: R63         Preferred and Common Stock - Additional             HTML     73K 
                Information (Details)                                            
79: R64         Equity Incentive Plans - Additional Information     HTML     82K 
                (Details)                                                        
80: R65         Equity Incentive Plans - Summary of Stock-based     HTML     34K 
                Compensation Expense (Details)                                   
81: R66         Equity Incentive Plans - Summary of Assumptions     HTML     39K 
                Used in Black-Scholes Option-pricing Model for                   
                Stock Options (Details)                                          
82: R67         Equity Incentive Plans - Summary of Option          HTML     87K 
                Activity (Details)                                               
83: R68         Net Loss Per Share Attributable to Common           HTML     59K 
                Stockholders - Summary of the Computation of Basic               
                and Diluted Net Loss Per Share Attributable to                   
                Common Stockholders (Details)                                    
84: R69         Net Loss Per Share Attributable to Common           HTML     32K 
                Stockholders - Schedule of Anti-Dilutive                         
                Securities Excluded from Computation of Earnings                 
                Per Share (Details)                                              
85: R70         Income Taxes - Summary of Reconciliation of         HTML     45K 
                Federal Statutory Income Tax Rate to Effective                   
                Income Tax Rate (Details)                                        
86: R71         Income Taxes - Summary of Components of Deferred    HTML     59K 
                Taxes (Details)                                                  
87: R72         Income Taxes - Additional Information (Details)     HTML     49K 
88: R73         Related Party Transactions - Additional             HTML     87K 
                Information (Details)                                            
89: R74         Employee Benefits - Additional Information          HTML     36K 
                (Details)                                                        
91: XML         IDEA XML File -- Filing Summary                      XML    172K 
94: XML         XBRL Instance -- omga-20231231_htm                   XML   1.87M 
90: EXCEL       IDEA Workbook of Financial Report Info              XLSX    126K 
15: EX-101.SCH  XBRL Taxonomy Extension Schema With Embedded         XSD   4.22M 
                Linkbases Document -- omga-20231231                              
92: JSON        XBRL Instance as JSON Data -- MetaLinks              643±   934K 
93: ZIP         XBRL Zipped Folder -- 0000950170-24-038094-xbrl      Zip   1.55M 


‘EXCEL’   —   IDEA Workbook of Financial Report Info


This is an IDEA Workbook.

        Download this Microsoft® Excel® .xlsx workbook


13 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

12/11/23  Omega Therapeutics, Inc.          8-K:5,9    12/11/23   11:510K                                   Donnelley … Solutions/FA
 9/22/23  Omega Therapeutics, Inc.          8-K:1,2     9/22/23   11:258K                                   Donnelley … Solutions/FA
 8/03/23  Omega Therapeutics, Inc.          8-K:1,2,9   8/03/23   13:481K                                   Donnelley … Solutions/FA
 8/03/23  Omega Therapeutics, Inc.          10-Q        6/30/23   81:10M                                    Donnelley … Solutions/FA
 7/13/23  Omega Therapeutics, Inc.          8-K:1,9     7/11/23   13:1M                                     Donnelley … Solutions/FA
 3/01/23  Omega Therapeutics, Inc.          10-K       12/31/22   91:15M                                    Donnelley … Solutions/FA
 2/23/23  Omega Therapeutics, Inc.          8-K:1,9     2/22/23   12:363K                                   Donnelley … Solutions/FA
 5/04/22  Omega Therapeutics, Inc.          10-Q        3/31/22   84:9.8M                                   Donnelley … Solutions/FA
 3/10/22  Omega Therapeutics, Inc.          10-K       12/31/21   96:20M                                    Donnelley … Solutions/FA
12/21/21  Omega Therapeutics, Inc.          8-K:1,2,9  12/20/21   11:302K                                   Donnelley … Solutions/FA
 8/03/21  Omega Therapeutics, Inc.          8-K:5,9     8/03/21    3:233K                                   Donnelley … Solutions/FA
 7/26/21  Omega Therapeutics, Inc.          S-1/A                 19:7.2M                                   Donnelley … Solutions/FA
 7/09/21  Omega Therapeutics, Inc.          S-1                   15:6.1M                                   Donnelley … Solutions/FA
Top
Filing Submission 0000950170-24-038094   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., May 14, 8:21:58.1am ET